Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2014  |  Volume : 10  |  Issue : 3  |  Page : 665-670

Synergistic anti-tumor effects of nitroreductase mutants and p53

1 Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Immunology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
3 Shiraz Institute for Cancer Research; Shiraz Pharmacy School, Shiraz University of Medical Sciences, Shiraz, Iran
4 Shiraz Institute for Cancer Research; Department of Immunology, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran
5 School of Cancer Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom

Correspondence Address:
Mahboobeh Razmkhah
Shiraz Institute for Cancer Research, Medical School, Shiraz University of Medical Sciences, Shiraz
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.139155

Rights and Permissions

Introduction: The p53 gene therapy showed promising results for treatment of numerous cancers particularly in combination with chemotherapy or radiotherapy. Gene therapy combining two or more treatment options may lead to the synergistic effects between diverse therapies and provide many opportunities in our fight against cancer. Aim: This study focused on the effects of p53 combining with the suicide gene therapy, nitroreductase (NTR)/5-(aziridin-1-yl)-2,4 dinitrobenzamide, on different cancer cell lines. Materials and Methods: Effects of adenoviral expressing p53 alone or in combination with wild type (WT) NTR, NTR single mutant, F124N and two NTR double mutants, T41L/N71S and T41L/F70A on survival rate of A549, QU-DB, MCF-7, MDA-MB-468 and DU145 cancer cell lines were determined by MTT assay. Expressions of MDM2 and TP53 transcripts were then assessed by quantitative real-time polymerase chain reaction in p53, NTR and combination of p53 with NTR infected cell lines. Results: According to the results, combination of p53 with NTR double mutant, T41L/F70A or NTR single mutant F124N, showed statistically significant decrease in vitality of all cancer cell lines studied compared with status of IC 50 from p53 or WT NTR and other NTR mutants alone (P < 0.05). Expressions of TP53 and MDM2 were downregulated in all T41L/F70A infected cells except for MCF-7. Conclusion: Combination of T41L/F70A NTR with p53 may have more advantages for treatment of different types of cancers compared to the other NTRs and p53 alone. The present study results may open new windows for getting desired outcome in gene therapy of different types of cancer.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded91    
    Comments [Add]    

Recommend this journal